Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines

被引:56
作者
Arlot-Bonnemains, Yannick [2 ]
Baldini, Enke [1 ]
Martin, Benedicte [2 ]
Delcros, Jean-Guy [2 ]
Toller, Matteo [3 ]
Curcio, Francesco [3 ]
Ambesi-Impiombato, Francesco S. [3 ]
D'Armiento, Massimino [1 ]
Ulisse, Salvatore [1 ]
机构
[1] Univ Roma La Sapienza, Dept Expt Med, I-00161 Rome, Italy
[2] Univ Rennes 1, CNRS, UMR Genet & Dev 6061, IFR 140 GFAS, F-35043 Rennes, France
[3] Univ Udine, Dept Pathol & Expt Med & Clin, I-33100 Udine, Italy
关键词
D O I
10.1677/ERC-08-0021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Anaplastic thyroid cancers (ATC) are aggressive tumors, which exhibit cell cycle misregulations leading to uncontrolled cellular proliferation and genomic instability. They fail to respond to chemotherapeutic agents and radiation therapy, and most patients die within a few months of diagnosis. In the present study, we evaluated the in vitro effects on ATC cells of VX-680, an inhibitor of the Aurora serine/threonine kinases involved in the regulation of multiple aspects of chromosome segregation and cytokinesis. The effects of VX-680 on proliferation, apoptosis, soft agar colony formation, cell cycle, and ploidy were tested on the ATC-derived cell lines CAL-62, 8305C, 8505C, and BHT-101. Treatment of the different ATC cells with VX-680 inhibited proliferation in a time- and dose-dependent manner, with the IC50 between 25 and 150 nM. The VX-680 significantly impaired the ability of the different cell lines to form colonies in soft agar. Analysis of caspase-3 activity showed that VX-680 induced apoptosis in the different cell lines. CAL-62 cells exposed for 12 h to VX-680 showed an accumulation of cells with >= 4N DNA content. Time-lapse analysis demonstrated that VX-680-treated CAL-62 cells exit metaphase without dividing. Moreover, histone H3 phosphorylation was abrogated following VX-680 treatment. In conclusion, our data demonstrated that VX-680 is effective in reducing cell growth of different ATC-derived cell lines and warrant further investigation to exploit its potential therapeutic value for ATC treatment.
引用
收藏
页码:559 / 568
页数:10
相关论文
共 43 条
[1]   Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment approaches [J].
Are, C ;
Shaha, AR .
ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (04) :453-464
[2]   Identification of a functional destruction box in the Xenopus laevis aurora-A kinase pEg2 [J].
Arlot-Bonnemains, Y ;
Klotzbucher, A ;
Giet, R ;
Uzbekov, R ;
Bihan, R ;
Prigent, C .
FEBS LETTERS, 2001, 508 (01) :149-152
[3]   The cellular geography of aurora kinases [J].
Carmena, M ;
Earnshaw, WC .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (11) :842-854
[4]   Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases [J].
Carter, TA ;
Wodicka, LM ;
Shah, NP ;
Velasco, AM ;
Fabian, MA ;
Treiber, DK ;
Milanov, ZV ;
Atteridge, CE ;
Biggs, WH ;
Edeen, PT ;
Floyd, M ;
Ford, JM ;
Grotzfeld, RM ;
Herrgard, S ;
Insko, DE ;
Mehta, SA ;
Patel, HK ;
Pao, W ;
Sawyers, CL ;
Varmus, H ;
Zarrinkar, PP ;
Lockhart, DJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (31) :11011-11016
[5]   Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function [J].
Chen, SS ;
Chang, PC ;
Cheng, YW ;
Tang, FM ;
Lin, YS .
EMBO JOURNAL, 2002, 21 (17) :4491-4499
[6]   Mitotic phosphorylation of histone H3: Spatio-temporal regulation by mammalian aurora kinases [J].
Crosio, C ;
Fimia, GM ;
Loury, R ;
Kimura, M ;
Okano, Y ;
Zhou, HY ;
Sen, S ;
Allis, CD ;
Sassone-Corsi, P .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (03) :874-885
[7]   LONG-TERM CULTURE AND FUNCTIONAL-CHARACTERIZATION OF FOLLICULAR CELLS FROM ADULT NORMAL HUMAN THYROIDS [J].
CURCIO, F ;
AMBESIIMPIOMBATO, FS ;
PERRELLA, G ;
COON, HG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (19) :9004-9008
[8]   Imatinib mesylate (Gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro [J].
Dziba, JM ;
Ain, KB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2127-2135
[9]   Minireview: Branded from the start - Distinct oncogenic initiating events may determine tumor fate in the thyroid [J].
Fagin, JA .
MOLECULAR ENDOCRINOLOGY, 2002, 16 (05) :903-911
[10]  
GIOANNI J, 1991, B CANCER, V78, P1053